Yusri Elsayed, M.D., M.H.Sc., Ph.D. is the Vice President, Hematologic Malignancies Disease Area Stronghold Leader, Interim Head Early Development at Janssen Research & Development, LLC, and has worked in all stages of drug development, on both small and large molecules. Yusri has played an important role in the Hematologic Malignancies DAS since its inception and is a member of the core team and the business development team. He also played an important role in the diligence and in-licensing of recent Hematologic Malignancies DAS assets.
Yusri joined Janssen in 2005 as Medical Director/Project Physician. Since then, he has held positions of increasing responsibility, including Medical Leader and, most recently, Senior Director, Early Development Global Clinical Leader, leading the clinical development of several early-phase compounds for multiple myeloma and various B-cell malignancies.
Before joining Janssen, Yusri led early-development studies of oncology drugs, including small molecules and monoclonal antibodies, at Bristol-Myers Squibb. Prior to that, he was Assistant Professor of Medicine at the Cancer Institute of New Jersey and at the University of Medicine and Dentistry of New Jersey -Robert Wood Johnson Medical School, where he was a Principal Investigator on numerous Phase 1 and investigational therapeutics trials and authored numerous publications.
Yusri completed his residency in Internal Medicine at State University of New York at Stony Brook (Nassau University Medical Center program) and trained in Medical Oncology at the National Cancer Institute and in Hematology at the National Heart, Lung and Blood Institute, both of which are part of the National Institutes of Health, Bethesda, Maryland. He is board certified in medical oncology and in hematology. Yusri also earned a master’s degree in clinical research from Duke University in Durham, North Carolina and a doctorate from Kyushu University in Japan.